2/26/2021CANbridge Pharma and Puma Biotech Agree to Terminate NERLYNX License...

2/26/2021Spring Promotion - Pharma China Publications (Free)

2/26/2021NMPA Announces Package Insert Revision of Misoprostol Tablets

2/26/2021Recent Executive Moves

2/26/2021Financial-related Company News in Brief

2/26/2021241 A Share-Listed Chinese MedPharm Cos Release 2020 Performance Guida...

2/25/2021Harbour BioMed Announces Chinese IND Approval of for Combo Therapy of ...

2/25/2021Puma Biotech and Pierre Fabre Amend NERLYNX License Deal to Include G...

2/25/2021China Approves Two More Domestic COVID-19 Vaccines (Free)

2/25/2021Snapshot of BMI System Financial Performance in 2020

2/25/2021AstraZeneca Gains Default Chinese IND Approval for Its Class 1 New Bio...

More>>

2/25/2021CANbridge Pharma and Puma Biotech Agree to Terminate NERLYNX License...

2/25/2021Biosecurity Law of the P.R.C. - Full Text Unofficial Translation

2/25/2021PharmaNJ's China NMPA Approved Tracker: Jan 2021

2/23/2021PharmaDJ's China Licensing Deals Tracker: Jan 2021

2/23/2021Review of Chinese Pharma Deals, R&D and Regulatory Developments in 202...

2/22/2021The Race to the Top: Does China Have What It Takes?

2/22/2021How Foreign Companies Can Break Into China's Biosimilar Market and Rel...

2/9/2021NLR: China's Patent Office Releases Draft Measures for Patent Linkage ...

2/9/2021SCMP: Phase One Trade Deal Largely A "Failure", As Purchases Fall Well...

2/8/2021Kantar: Chinese Physicians' Digital Behaviour During COVID-19 Outbreak

2/4/2021Changes To Biotech And Chemical Patent Examination - Recent Amendments...

More>>